Problem
India has ~1.3M registered doctors, the majority running solo or small Tier-2/3 clinics with no EMR and no support staff for documentation. Every patient visit forces a doctor to choose between talking to the patient and scribbling notes, and most clinics still hand-write prescriptions that get lost or misread. This wastes 3-5 minutes per consult and produces records that can't be searched, audited, or shared with the patient later.
Solution
A mobile app that records (with consent) the doctor-patient conversation in Hindi/English/regional languages, transcribes it with a vernacular-tuned speech model, and auto-generates a structured visit note (chief complaint, findings, plan) plus a draft prescription the doctor reviews and signs with one tap. The app then sends a plain-language summary and prescription image to the patient over WhatsApp. V1 ships as an Android app + lightweight web dashboard, no integration with hospital systems required.
Why Now
Product Hunt's June 2026 leaderboard is dominated by ambient AI teammates like Mina Meeting Assistant — tools that sit in a conversation, transcribe, and produce structured output in real time — proving the pattern has crossed from novelty to mainstream workflow tool. Cheap, accurate vernacular speech-to-text and on-device LLMs (the same wave behind Typeahead's local-AI writing assistant) now make this viable at India price points, which wasn't true even 18 months ago.
Target User
First 1,000 customers: solo-practice MBBS/general physicians in Tier-2 cities (Indore, Coimbatore, Lucknow, Nashik) seeing 30-60 patients/day, aged 35-55, earning ₹8-25L/year, who already use WhatsApp for patient follow-ups and are frustrated by handwriting prescriptions and end-of-day paperwork.
Business Model
₹1,499/month per doctor subscription (SaaS), sold via direct outreach through medical association chapters and rep referrals. At scale, marginal cost is speech-to-text + LLM API calls (~₹150-250/doctor/month), yielding ~75-80% gross margin. Secondary revenue: anonymized aggregate prescribing-pattern insights licensed to pharma (post product-market fit, with consent).
Competitive Landscape
- Direct (India): none yet at the Tier-2 solo-clinic price point — existing EMR players (Practo, Plum) target hospitals/chains, not solo GPs
- Direct (global reference): Abridge and Nabla (US ambient clinical scribes), and the Mina Meeting Assistant pattern broadly
- Why we win: vernacular-first transcription tuned to Indian medical shorthand and clinic slang, plus a WhatsApp-native delivery flow that fits how Tier-2 doctors already communicate with patients — both gaps the US-style scribes and Indian hospital EMRs ignore
6-Month Plan
- Month 1-2: Build core record → transcribe → structured-note pipeline (Hindi + English), recruit 10 pilot doctors
- Month 3: Add prescription-draft generation and WhatsApp patient-summary delivery; refine on pilot feedback
- Month 4: Add 2 more regional languages (Tamil, Marathi) based on pilot clinic locations; start paid conversion
- Month 5: Hire 1 field rep, launch through 2 medical association chapters, target 150 paying doctors
- Month 6: Add offline-first mode for low-connectivity clinics; target 400 paying doctors and ₹20L/month run-rate validation
- Budget: ₹7L (2 devs ₹4L, API/infra ₹1L, rep + travel ₹1.5L, association partnerships ₹0.5L), leaving ~₹13L of the ₹20L runway as buffer
Risks
- Doctor trust/adoption (high likelihood, high impact): doctors may distrust AI-drafted prescriptions or find recording awkward in front of patients — mitigate with an opt-in "review and sign" step that keeps the doctor fully in control
- Vernacular transcription accuracy (medium likelihood, high impact): Indian medical speech mixes languages and shorthand; poor accuracy kills trust fast — mitigate by starting with 2 well-resourced languages and a fast doctor-correction feedback loop that retrains the model
- Regulatory drift (low likelihood, high impact): if the product is perceived as offering diagnostic suggestions rather than documentation support, it could trigger DCGI medical-device scrutiny — mitigate by keeping all clinical judgment with the doctor and explicitly marketing as a documentation/admin tool only
Score Breakdown
- Market (14/20): ~1.3M Indian doctors, most without EMR tools; a ₹1,499/month SaaS reaching even 5% of Tier-2/3 GPs implies a multi-hundred-crore TAM within 3 years
- Capital (13/15): MVP needs only speech-to-text + LLM APIs and a mobile app — no hardware, no inventory; fits comfortably in ₹7L with 12-month runway inside ₹20L
- Team (8/10): two developers plus a part-time clinical advisor can ship a working v1 in ~9 weeks
- Trend (13/15): directly rides the ambient-AI-scribe wave topping Product Hunt's June 2026 leaderboard (Mina Meeting Assistant), applied to an underserved Indian vertical
- Moat (11/15): vernacular medical-speech tuning plus a growing correction dataset from real consultations creates a data flywheel and switching cost once doctors' note templates live in the system
- Economics (12/15): ~75-80% gross margin at scale on a recurring per-doctor subscription, with low marginal API cost per consult
- Speed (7/10): ~9 weeks to a working pilot since it needs no hospital integrations, just a recording app and an LLM pipeline, though vernacular tuning adds some lead time